Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
June 02, 2025 04:00 ET Â | Source: Aravax MELBOURNE, Australia and OXFORD,…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
adidas launches RS15 Avaglide A Rugby Boot built by and for Womens Rugby Players
RS15 Avaglide is a women’s specific boot, built to support the performance…
WISeKey to Present at Maxim Tech Conference Discover the Innovations Reshaping Tomorrow on June 3 at 8:30am ET
June 02, 2025 01:00 ET Â | Source: Wisekey International Holding Ltd. WISeKey…
Vodafone Qatar selects Nokia in major network modernization deal to drive expanded 5G coverage, reliability, and services
Press ReleaseVodafone Qatar selects Nokia in major network modernization deal to drive…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…
oneworld alliance Strengthens Leadership Team With Three Key Appointments
DELHI, India, May 31, 2025 /PRNewswire/ -- oneworld® alliance today continues to…
